<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="147959">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01864187</url>
  </required_header>
  <id_info>
    <org_study_id>YMTMD-0001</org_study_id>
    <nct_id>NCT01864187</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Dexmedetomidine in Obesity</brief_title>
  <official_title>A Study of the Pharmacokinetics of Dexmedetomidine in Obesity.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou General Hospital of Guangzhou Military Command</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou General Hospital of Guangzhou Military Command</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dexmedetomidine hydrochloride is a highly selective, potent a2-adrenoceptor agonist with
      significant analgesic, sedative and anxiolytic effects. In China, it is a relatively new
      drug. And as the population of obesity becomes larger, but whether the pharmacokinetics of
      the drug in Chinese who are obese is the same to normal people is unknown. So the
      investigators design this research to study the pharmacokinetics of dexmedetomidine in
      obesity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For the obese are sensitive to the disease such as hypertension, ischaemic heart disease and
      diabetes, the changes of the state may affect the pharmacokinetics of dexmedetomidine.
      Besides,the clearance of dexmedetomidine is parallel with liver function and it is excreted
      by kidney, so differences in the obese may be expected.

      About 10 obese patients and 10 matched healthy volunteers with normal weight would be chosen
      to receive a normal dosage of dexmedetomidine. And venous samples will be collected in
      different time points. Next the investigators can get the plasma concentration of
      dexmedetomidine by the use of HPLC-MS. And then the plasma concentration could be analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Plasma Concentration of dexmedetomidine</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 45 , 60, 90, 120, 150,180,240,360,480 hours post‐dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each team will be administered for 1μg/kg of dexmedetomidine eace one.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>The volunteers would receive a dosage of dexmedetomidine by 1μg/kg.</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Weight:28≦BMI≦45 and 18.5≦BMI≦24

          2. Written informed consent from the patient or the relatives of the participating
             patient.

        Exclusion Criteria:

          1. A previous history of intolerance to the study drug or related compounds and
             additives.

          2. Existing significant haematological, endocrine, metabolic or gastrointestinal
             disease.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>bo xu</last_name>
    <phone>88653387</phone>
    <phone_ext>020</phone_ext>
    <email>xubo333@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangzhou Military Region General Hospital, Department of Anesthesiology</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Zhi Li</last_name>
      <phone>15625052815</phone>
      <phone_ext>86</phone_ext>
      <email>lytow@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Iirola T, Aantaa R, Laitio R, Kentala E, Lahtinen M, Wighton A, Garratt C, Ahtola-Sätilä T, Olkkola KT. Pharmacokinetics of prolonged infusion of high-dose dexmedetomidine in critically ill patients. Crit Care. 2011;15(5):R257. doi: 10.1186/cc10518. Epub 2011 Oct 26.</citation>
    <PMID>22030215</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 12, 2013</lastchanged_date>
  <firstreceived_date>May 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou General Hospital of Guangzhou Military Command</investigator_affiliation>
    <investigator_full_name>bo xu</investigator_full_name>
    <investigator_title>associate chief physician</investigator_title>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Obesity</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
